Financial Comparison: Palvella Therapeutics (PVLA) and Its Rivals

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,067 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Palvella Therapeutics to similar businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, institutional ownership and profitability.

Earnings and Valuation

This table compares Palvella Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.33
Palvella Therapeutics Competitors	$9.25 billion	$124.46 million	-5.94

Palvella Therapeutics’ competitors have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations for Palvella Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	3	0	3.00
Palvella Therapeutics Competitors	8063	21681	49436	1296	2.55

Palvella Therapeutics presently has a consensus target price of $41.00, indicating a potential upside of 153.87%. As a group, “Pharmaceutical preparations” companies have a potential upside of 241.99%. Given Palvella Therapeutics’ competitors higher possible upside, analysts clearly believe Palvella Therapeutics has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 6.4% of Palvella Therapeutics shares are held by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Palvella Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.38%	-220.04%	-32.84%

Volatility and Risk

Palvella Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ competitors have a beta of 3.68, indicating that their average share price is 268% more volatile than the S&P 500.

Summary

Palvella Therapeutics competitors beat Palvella Therapeutics on 8 of the 13 factors compared.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.